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Unresolved inflammation is associated with several widely occurring diseases such as
arthritis, periodontal diseases, cancer, and atherosclerosis. Endogenous mechanisms that
curtail excessive inflammation and prompt its timely resolution are of considerable interest.
In recent years, previously unrecognized chemical mediators derived from polyunsaturated
fatty acids were identified that control the acute inflammatory response by activating local
resolution programs. Among these are the so-called specialized pro-resolving lipid media-
tors (SPMs) that include lipoxins (LX), resolvins (Rv), protectins (PD), and maresins (MaR),
because they are enzymatically biosynthesized during resolution of self-limited inflamma-
tion.They each possess distinct chemical structures and regulate cellular pathways by their
ability to activate pro-resolving G-protein coupled receptors (GPCRs) in a stereospecific
manner. For instance, RvD1 controls several miRNAs of interest in self-limited acute inflam-
mation that counter-regulate the mediators and proteins that are involved in inflammation.
Here, we overview some of the biosynthesis and mechanisms of SPM actions with focus
on the recently reported miR involved in their pro-resolving responses that underscore
their beneficial actions in the regulation of acute inflammation and its timely resolution.
The elucidation of these mechanisms operating in vivo to keep acute inflammation within
physiologic boundaries as well as stimulate resolution have opened resolution pharma-
cology and many new opportunities to target inflammation-related human pathologies via
activating resolution mechanisms.
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ACUTE INFLAMMATION: A PROTECTIVE HOST RESPONSE
THAT CAN TURN HARMFUL
Acute inflammation is a defensive physiological response occur-
ring in vascularized tissues to protect the host against injuries
(Majno and Joris, 1996). This formidable ally manifests its impor-
tant role, for instance, in the early phase after a microbial infection,
when it fights against invading pathogens before the adaptive
immune system is engaged (Abbas et al., 2011). The characteristic
“cardinal signs” of inflammation, described by the Roman physi-
cian Celsus in the first century, rubor (redness), tumor (swelling),
calor (heat), and dolor (pain), are the macroscopic manifesta-
tion of changes that occur at molecular and cellular levels in
inflamed tissues. Tissue edema is one of the earliest events in the
acute inflammatory response that arises from increased vascular
permeability of the microvasculature (Figure 1). Leukocytes are
then recruited at sites of inflammation and traverse postcapillary
venules. Polymorphonuclear neutrophils (PMN) are among the
first leukocyte responders that accumulate in the inflamed site.
As they are the first line of defense of the innate immune system,
these cells kill pathogens by engulfing them via phagocytosis and
release of microbicidal proteins stored in their intracellular gran-
ules and reactive oxygen species into phagolysosomal vacuoles
to kill invaders (Majno and Joris, 1996). Next, in experimental
acute inflammation, mononuclear cells enter the inflammatory
site. They can differentiate into macrophages (MΦs) and clear
microbes, cellular debris, and apoptotic PMN by phagocytosis in
a non-phlogistic process termed efferocytosis (Honn et al., 1989;
Gordon, 2007; Serhan et al., 2007).
Ultimately, the clearance and efflux of phagocytes allow for
resolution of the tissue and the return to homeostasis, namely
catabasis (Figure 1). In order to maintain a healthy status, both
the initiation of acute inflammation and its resolution must be
efficient. Notably, it is not how often or how extensive an acute
inflammatory reaction starts, but how effectively and quickly it
resolves that determines whether the battle of inflammation is
detrimental or the ideal favorable outcome for the host. Indeed,
uncontrolled or unresolved inflammation is now recognized as a
major driver of human pathologies, including arthritis, asthma,
cancers, and cardiovascular diseases (Serhan, 2004; Serhan and
Savill, 2005; Nathan and Ding, 2010). Given the high occur-
rence of these and many other diseases, understanding how acute
inflammation resolves is of wide interest.
This review focuses on the specialized pro-resolving media-
tors (SPM) that are biosynthesized from essential polyunsaturated
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FIGURE 1 | Cellular and molecular mediators in acute inflammation and
resolution. Surgical intervention, tissue injuries, or microbial infections in
vascularized tissues evoke a rapid acute inflammatory response
characterized by a rapid exudate formation with edema, leukocyte infiltration,
and serum proteins. Polymorphonuclear leukocytes (PMN) are among the
first responders that fight microbes followed by monocytes that differentiate
locally into pro-resolving macrophages (MΦs). Efferocytosis of apoptotic
PMN and microbes by pro-resolving MΦs and subsequent egress via
lymphatics are hallmarks of tissue resolution. Redness and swelling, two of
the cardinal signs of inflammation, can be easily appreciated in the example
of eye and skin inflammation shown in the right panel. A few days later,
inflammation is almost completely resolved and homeostasis re-established.
(Pictures were taken using a Lumix SZ7 digital camera). Lipid autacoids
prostaglandins (PGs) and leukotrienes (LTs) are classical mediators of the
onset phase of inflammation, promoting edema, PMN recruitment, and pain.
By sustaining inflammation, PGs and LTs can lead to chronic inflammation
and tissue damage. Specialized pro-resolving lipid mediators (SPMs) are
biosynthesized within resolving exudates and proved to be very potent in
reducing further PMN infiltration, stimulating non-phlogistic MΦ
efferocytosis, promoting tissue regeneration, and controlling pain. Recent
advances have demonstrated that specific miRNAs and microparticles can
possess pro-resolving properties.
fatty acids (PUFAs), arachidonic acid (AA), eicosapentaenoic acid
(EPA), and docosahexaenoic acid (DHA), namely lipoxins (LX),
resolvins (Rv), protectins (PD), and maresins (MaR) and on their
biosynthetic pathways, receptors, and miRNAs that act to control
self-limited inflammation and promote its timely resolution. For
readers interested in the biosynthesis of Rv and PD, this subject
was recently reviewed in detail in Bannenberg and Serhan (2010),
and the confirmation and total organic synthesis in Serhan and
Petasis (2011).
RESOLUTION IS AN ACTIVE PROCESS CONTROLLED BY SPM:
SELF-LIMITED EXPERIMENTAL SYSTEM
At the histological level, resolution was well described by pathol-
ogists for more than 100 years as the time when the neutrophils
that infiltrated the inflamed tissue sites leave or are lost from the
site (Majno and Joris, 1996). Traditionally, resolution was thought
to be a passive process, simply due to the attenuation/dissipation
of chemotactic and pro-inflammatory signals. Our results (Ser-
han et al., 2000a; Levy et al., 2001), followed by those from
many others worldwide (reviewed in a consensus report in Ser-
han et al., 2007) demonstrated that resolution is instead an active
process orchestrated by special novel chemical mediators that turn
on biochemical and cellular pathways to enable the return to
homeostasis.
Lipid mediators (LM) from PUFA play essential roles in distinct
phases of acute inflammation, with prostaglandins (PGs; Flower,
2006; Samuelsson, 2012) and cysteinyl leukotrienes (cysLTs) pro-
moting early increase in vascular permeability and leukotriene
(LT) B4 acting as a potent leukocyte chemoattractant (Samuels-
son, 1983). Prostaglandins also contribute to fever and pain
Frontiers in Immunology | Inflammation October 2012 | Volume 3 | Article 298 | 2
Recchiuti and Serhan Resolving mechanisms in inflammation
(von Euler, 1973). Chronic inflammation is widely viewed as
an excess of pro-inflammatory mediators (Figure 1; Nathan and
Ding, 2010). Results from our laboratory first demonstrated that
the resolution phase is characterized by the active biosynthesis
of specific LM that operate as “resolution agonists” to a) keep
inflammation within physiological boundaries and b) expedite
the complete return to homeostasis (Figure 1). The identifica-
tion of this new array of LM was achieved using self-limited
or naturally resolving acute inflammation models in vivo and
a systems approach (Serhan et al., 2000a, 2002). The pharma-
cologic impact of the Rv and PD was reviewed in (Serhan
and Chiang, 2008). This new array of LM is now recognized
as a genus of SPM (Serhan and Chiang, 2008) that have two
broad functions and are anti-inflammatory and pro-resolving
via stimulating multi-level actions. Accruing evidence indicates
that failure or disruption of the endogenous pro-resolution path-
ways governed by SPM can be detrimental and underlie some
of the mechanisms of chronic inflammatory diseases (Gilroy
et al., 1999; Karp et al., 2004; Schwab et al., 2007; Chan and
Moore, 2010). SPM exert their potent dual anti-inflammatory
and pro-resolving activities in the low nano- to microgram dose
range when added back into experimental inflammatory disease
models (Serhan and Chiang, 2008) and provide biotemplates
for the design of novel therapeutics currently in clinical trials
(see http://Clinicaltrials.Gov Identifier: NCT00799552). There-
fore, harnessing these SPM may provide fascinating opportunities
in the new and uncharted terrain of resolution pharmacology,
with a substantial shift from a depletion pharmacology (i.e., via
inhibitors, blockers, antagonists) toward a new approach based
on resolution agonists that activate endogenous protective and
clearance mechanisms.
Additional chemical mediators are operative in inflamed tissues
to switch off leukocyte infiltration and restore their physiolog-
ical functions. Among these are several cytokines (e.g., TGFβ,
IL-10) that accumulate in resolving exudates (Bannenberg et al.,
2005); glucocorticoids and the glucocorticoid-induced annexin-1
protein, which tune the inflammatory response and bring about
homeostasis (for a recent review see (Perretti and Dalli, 2009));
and the transcription factor NF-κB, which also carries some
anti-inflammatory properties (Lawrence et al., 2001). Moreover,
inducing PMN apoptosis as well as lymphoid cells while stimulat-
ing their prompt removal by MΦs also can promote resolution
(Honn et al., 1989; Ariel et al., 2006). Recent results indicate
that small inhibitors of cyclin-dependent kinases fulfill this goal
(Leitch et al., 2012) as do annexin-1 peptides (Perretti and Dalli,
2009). Therefore, the resolution process can be pharmacologically
targeted.
Importantly, resolution is not synonymous with endogenous
anti-inflammation. This is because, in order to be considered a
“pro-resolver,” a chemical and/or molecular entity, in addition to
serving as a“stop signal”for neutrophil trafficking and other cardi-
nal signs of inflammation (e.g., swelling, pain), must also stimulate
efferocytosis by MΦ, favor the antibacterial activities, and promote
tissue repair and regeneration to achieve homeostasis. Along these
lines, PGE2 can have anti-inflammatory properties in certain set-
tings via stimulation of cAMP, but is not acting as pro-resolver
since it does not enhance the uptake and clearance of apoptotic
cells by MΦs (Kunkel et al., 1981). Also, although cyclooxygenase
(COX) inhibitors as well as certain lipoxygenase (LO) inhibitors
reduce some of the cellular events of the inflammatory reaction
(e.g., edema formation, PMN recruitment, and pain), they dra-
matically impact the endogenous pro-resolution circuits and may
delay or even derange this ideal outcome of acute inflammation
and thus are “resolution toxic” (Gilroy et al., 1999; Schwab et al.,
2007). In contrast, aspirin and glucocorticoids work synergisti-
cally with endogenous pro-resolution pathways (Perretti et al.,
2002).
Complete resolution also requires the clearance of the rem-
nants of damaged tissues and activated or apopotic cells, so-called
microparticles (MPs). Originally viewed merely as empty vesi-
cles, MPs are now recognized as “specialized shuttles” used by
the organism to transfer bioactive molecules from cell to cell.
Their role in inflammation and resolution is now being appreci-
ated. Recently, the anti-inflammatory properties of a PMN-derived
sub-population of MPs were uncovered, where they appear to
signal to activate resolution mechanisms (Gasser and Schifferli,
2004; Dalli et al., 2008; Norling et al., 2011). Mimicking this
new endogenous mechanism in resolution, novel human PMN-
derived nanoparticles containing AT-RvD1 or a LXA4 stable ana-
log, termed humanized pro-resolving nanomedicines, were pre-
pared. These SPM-enriched nanohumanized particles possessed
beneficial bioactivities in reducing acute inflammation in vivo,
expediting resolution, and promoting wound healing (Norling
et al., 2011). Hence, NPs can serve as mimetics of endogenous
pro-resolution pathways (Figure 1).
Active resolution includes gene expression regulation of several
soluble chemical mediators (e.g., cytokines, chemokines), recep-
tors (e.g., Toll-like receptors), as well as transcription factors.
An emerging line of investigation indicates that many genes are
under tight control of miRNAs, short non-coding RNA molecules
that act as translational repressors of mRNA transcripts (Bartel,
2009). They are involved in many physiological and pathological
processes, including cell development, cancer (Iorio and Croce,
2009), and inflammation (Sheedy and O’Neill, 2008; Alam and
O’Neill, 2011; O’Neill et al., 2011). Our recent results uncovered
roles of miRNAs in self-limited inflammation and in the resolution
phase, specifically, RvD1-G-protein coupled receptor-dependent
gene networks in resolution of acute inflammation as part of the
endogenous circuitry that controls this active process (Recchiuti
et al., 2011; Krishnamoorthy et al., 2012).
IDENTIFYING SPM IN RESOLUTION
An unbiased systems approach was taken to identify the endoge-
nous SPM and decode their mechanisms of action in resolution.
For this, the murine dorsal air pouch and self-limited acute
inflammation was ideal because it permitted isolation of con-
tained inflammatory exudates (Serhan et al., 2000a, 2002) and
also enabled direct LM lipidomics of bioactive products, as well as
their inactive precursors and further metabolites, proteomics, and
analyses of cellular composition of the resolving exudate; namely
the natural means by which inflammation returns to resolution
and homeostasis. With this systems approach it was also possible
to establish the local and temporal dissociation of LM biosyn-
thesis (Bannenberg et al., 2005). For example, upon initiation
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of inflammation with TNF-α, there was a typical acute-phase
response characterized by rapid PMN infiltration preceded by local
generation of both PGs and LTs. Unexpectedly, the eicosanoids
undergo what was termed earlier a “class switch” and the profiles
of LM made within this milieu switched with time (Levy et al.,
2001). Indeed, the potent chemoattractants LT were deactivated
and 15-LO required for LX and Rv production was transcription-
ally activated (Levy et al., 2001). Notably, the omega-3 essential
fatty acids DHA and EPA are precursors of Rv, PD, and MaR, are
rapidly carried into the exudates via plasma edema and are then
made available for conversion for the congregated exudate cells
(Kasuga et al., 2008). Of interest, this LM class switching is driven
in part by COX-derived PGE2 and D2, via transcriptional regu-
lation of enzymes involved in LX biosynthesis (Levy et al., 2001).
Hence, the concept that “alpha signals omega,” namely the begin-
ning signals the end in inflammation, was introduced by Sir John
Savill and one of us to emphasize this finding (Serhan and Sav-
ill, 2005) to note that at time zero mediators are biosynthesized
that signal to limit PMN influx and terminate the contained acute
inflammatory response.
WHAT IS A LIPID MEDIATOR?
To qualify as a LM, a product must be stereoselective in its actions
and be produced in amounts that are commensurate with its
potency and range of action (Serhan et al., 1996). Along this line,
LX, Rv, and PD are present in human serum in pM to nM amount
(e.g., LXA4,∼1.4 nM; RvD1,∼50 pM; RvE1,∼0.5 nM; values from
the Serum Metabolome Project; Psychogios et al., 2011; see also
Oh et al., 2011 for RvE1 and Oh et al., 2012 for RvE2 values)
in human peripheral blood samples from healthy donors. LM
lipidomics using liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS) coupled with informatics permit profiling of
closely related compounds and identification of new molecules.
Retrograde synthesis, both biogenic and total organic, allows the
complete elucidation of chemical structure, stereochemistry, and
physical properties, along with the recapitulation of the in vivo
biosynthetic pathway (for examples see Sun et al., 2007; Serhan
et al., 2009). The matching/identification of LM is usually carried
out with at least two different instruments and/or mobile phase
solvent systems and the criteria to identify a known LM are the
following: (a) LC retention time should match by coelution with
the LM authentic standard; (b) UV chromophore should match
the synthetic and authentic LM (i.e.,λmax and band shape); as well
as (c)≥6 diagnostic ions of tandem MS/MS spectrum (Figure 2).
Also, the LC-MS/MS fragmentation mechanisms for the Rv and
PD D1 and related DHA-derived products have been studied using
deuterium-labeled compounds that facilitated their identification
in vivo (Hong et al., 2007).
LIPOXINS
Lipoxin A4 and B4 were the first anti-inflammatory LM recog-
nized to possess pro-resolving actions (Serhan et al., 1984a,b;
Maddox et al., 1997; Takano et al., 1998; Godson et al., 2000).
Although LXs were first isolated and identified in the 1980s in the
Samuelsson laboratory (Serhan et al., 1984a), their potent bioac-
tions were uncovered some years later with the identification of
the aspirin-triggered LX (ATL; Claria and Serhan, 1995) and the
design of ATL stable analogs (Serhan et al., 1995; vide infra), when
it became clear that they act as “braking signals” of further PMN
infiltration (Takano et al., 1998) and as potent stimuli for the
non-phlogistic recruitment of monocytes (Maddox et al., 1997)
and MΦ efferocytosis (Godson et al., 2000; recently reviewed in
Serhan, 2005; Spite and Serhan, 2011). LXs are lipoxygenase inter-
action products derived from the enzymatic conversion of AA
via transcellular biosynthesis during cell–cell interactions occur-
ring during inflammation (Samuelsson et al., 1987). In humans,
sequential oxygenation of AA by 15-LO and 5-LO, followed by
enzymatic hydrolysis, leads to the biosynthesis of LXA4 and B4 in
mucosal tissues, such as airways, gastrointestinal tract, and oral
cavity (Edenius et al., 1990; Levy et al., 1993; Gronert et al., 1998;
Figure 3 and reviewed in Romano (2010). Blood vessels represent
a second site for LX biosynthesis, with the conversion of 5-LO-
derived LTA4 into LXA4 and B4 by 12-LO in platelets (Serhan and
Sheppard, 1990; Romano and Serhan, 1992; Romano, 2010).
ATL: THE FIRST ASPIRIN-TRIGGERED MEDIATORS
A third LX synthetic pathway is initiated by aspirin, the well-
known derivative of salicylates, by acetylation of COX-2. This
covalent modification shifts the enzyme activity from endoperoxi-
dase to lipoxygenase-like, and COX-2 converts AA into 15R-HETE,
which is a substrate of leukocyte 5-LO for the biosynthesis of 15R-
epi-LXA4 and B4 (Claria and Serhan, 1995). Hence, among the
non-steroidal anti-inflammatory drugs (NSAID), aspirin has the
unique capability to “jump start” resolution by its ability to trig-
ger endogenous biosynthesis of so-called “aspirin-triggered” LX
(Figure 3) Notably,ATL produced in vivo in human subjects taking
aspirin (Chiang et al., 2004) proved to mediate the local anti-
inflammatory actions of low-dose aspirin in healthy individuals
(Morris et al., 2009).
SPM BIOSYNTHESIZED FROM OMEGA-3 POLYUNSATURATED FATTY
ACIDS: LOCAL MEDIATORS
The essential roles of omega-3 PUFA in health were evident in 1929
(Burr and Burr, 1929), andω-3, also known as n-3 PUFA EPA and
DHA, have beneficial effects in human diseases including poten-
tial antithrombotic, immunoregulatory, and anti-inflammatory
properties (Iigo et al., 1997; De Caterina, 2011). Also, the Gruppo
Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico-
Prevenzione trial evaluated the effects of ω-3 PUFA supplementa-
tion with>11,000 patients surviving myocardial infarction taking
>1 g ofω-3 PUFA daily along with recommended preventive treat-
ments including aspirin, and reported a significant benefit with
a decrease in cardiovascular death (GISSI-Prevenzione Investiga-
tors, 1999). It is believed that the actions of the major lipid of
fish oil EPA (C20:5) are based upon (a) preventing conversion of
AA to proinflammatory and prothrombotic eicosanoids; (b) serv-
ing as an alternate substrate for the five-series LTs that are less
potent than four-series LTs; and (c) conversion by COX to three-
series prostanoids (i.e., PGI3) that also maintain antithrombotic
actions. These and other explanations offered (Iigo et al., 1997;
Calder, 2009; De Caterina, 2011) have not been generally accepted
because of the lack of molecular evidence in vivo and the high con-
centrations of ω-3 PUFA required to achieve putative “beneficial
actions” in in vitro cell culture experiments.
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FIGURE 2 | Strategy for functional profiling of SPM in resolving
exudates. (A) During self-limited inflammation, murine exudates (a “good
and laudable” pus according to ancient physicians; Majno, 1991) as well as
human leukocytes biosynthesize SPM, which include the lipoxins, E-series
resolvins, D-series resolvins, protectins (neuroprotectin D1), and maresins,
which work to keep the inflammatory response within physiological
boundaries and help to expedite the return to homeostasis. Functional
profiling takes advantage of liquid chromatography-ultraviolet
spectrometry-tandem mass spectrometry (LC-UV-MS/MS) for identifying and
quantifying SPM. Gas chromatography-mass spectrometry (GC-MS) is also
useful to provide additional information together with LC-UV-MS/MS to
support structural identification and proposed structures. Retrograde analysis
with biogenic synthesis using isolated human cells and total organic synthesis
allows the assignment of chirality and double bond geometries using H-NMR
with synthetic materials and matching studies (see text; Fiore et al., 1991;
Serhan et al., 2000a, 2002, 2006, 2012; Sun et al., 2007; Spite et al., 2009a;
Krishnamoorthy et al., 2010 for details). Bioactions of SPM are assessed in
both animal models and human cell systems. They must be stereoselective
and evident at concentrations/doses that are commensurate with the amount
of SPM produced. (B) Example of RvD1 stereoselective total organic
synthesis (reported in Sun et al., 2007); for further details (see Serhan and
Petasis, 2011) for a recent review of organic synthesis.
To address the molecular basis for anti-inflammatory proper-
ties of ω-3 fatty acids, an unbiased LC-MS/MS-based informatics
approach was developed to identify novel mediators generated
from ω-3 precursors during acute inflammation in vivo. Using
this approach, EPA and DHA were found to be enzymatically
converted into novel potent LMs coined Rv, an acronym of
resolution phase interaction products, because they: (a) are pro-
duced during cell–cell interactions occurring in the resolution
phase of acute inflammatory response; (b) “stop” further neu-
trophil entry to sites of inflammation, and (c) reduce exudates
(Serhan et al., 2000a, 2002, 2006; Hong et al., 2003; Bannen-
berg et al., 2005). Rv represented an entirely new family of
mediators produced from the ω-3 fatty acids and importantly
they appeared during the resolution phase via active biosyn-
thetic processes. The biosynthesis of Rv gives rise to stereospecific
local mediators that have potent actions and activate specific
receptors.
E-SERIES RESOLVINS
EPA-derived E-series Rv are endogenously biosynthesized in vivo
in resolving murine exudates and in isolated human cells systems
by isolated cells (e.g., endothelial cell-leukocyte interaction) and in
whole blood (vide infra). The complete stereochemistry of the first
member of this family, RvE1, has been established as 5S,12R,18R-
trihydoxy-6Z,8E,10E,14Z,16E-EPA (Arita et al., 2005a). For fur-
ther details on the total organic synthesis (see Serhan and Petasis,
2011). Within vascular endothelial cells, aspirin-acetylated COX-
2 converts EPA into 18R-hydro(peroxy)-eicosapentaenoic acid
(HEPE), which is rapidly taken up by activated leukocytes (e.g.,
PMN) and further metabolized into RvE1. Notably, quantitative
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FIGURE 3 | Biosynthetic schemes of SPM. (A) In humans, AA can be
converted into 15S-H(p)-ETE through 15-LO and into 15R-H(p)-ETE by aspirin
(ASA)-acetylated COX-2. Both intermediates can be further metabolized through
5-LO and enzymatic hydrolysis yielding LXA4 or 15-epi-LXA4. (B) E-series
resolvins are biosynthesized via conversion of EPA by ASA-acetylated COX-2.
Products of these reactions, 18S-H(p)-EPE and 18R-H(p)-EPE, are rapidly taken
up by 5-LO and converted to 18S-RvE1 and RvE1. (C) The DHA metabolome
includes several SPM biosynthesized via 15/5-LO and ASA-acetylated COX-2.
Each SPM is biosynthesized via distinct biochemical routes involving
stereocontrolled oxygenation, epoxide formation, and enzymatic hydrolysis. The
main structures of key SPM and their biosynthetic routes (with precursors and
main enzymes involved) are depicted (see text and Serhan and Petasis, 2011 for
further details). The complete stereochemistry of each of these SPM is
established, total organic synthesis achieved, and bioactions confirmed.
chiral HPLC analysis indicated that the 18R-HEPE isomer was
dominant to its epimer 18S-HEPE in human plasma from healthy
subjects taking EPA (Oh et al., 2011). In contrast, human subjects
who were administered aspirin before EPA had more 18S- than
18R-HEPE, indicating that aspirin might promote 18S-HEPE pro-
duction as well as 18R-HEPE from ingested EPA (Oh et al., 2011).
This 18S-HEPE can also be converted to epimeric RvE1 and RvE2
by human recombinant 5-LO and LTA4 hydrolase (LTA4H), known
as pro-inflammatory LTB4-synthesizing enzymes (Oh et al., 2011).
RvE1 is also produced in vivo through an aspirin-independent
pathway via cytochrome P450-driven oxygenation of EPA (Serhan
et al., 2000b). Of interest, RvE1 was also found to be produced
by Candida albicans and appears to be involved in clearance of
this organism (Haas-Stapleton et al., 2007). Thus RvE1 has multi-
ple biosynthetic routes. RvE2 (5S,18-dihydroxy-EPE) is biosyn-
thesized in resolving exudates and in human whole blood via
reduction of 5S-hydroperoxy,18-hydroxy-EPE, an intermediate in
the biosynthetic pathway of RvE1 (Tjonahen et al., 2006; Ogawa
et al., 2009; Oh et al., 2012; Figure 3).
D-SERIES RESOLVINS
Earlier investigations using LC-MS/MS lipidomics of resolving
exudates from mice given DHA and aspirin provided the first
evidence of novel endogenous routes that lead to the forma-
tion of 17-hydroxy-containing mediators. Gaining information
on how human tissue and cells may produce D-series Rv involved
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the in vitro recapitulation of biosynthetic pathways using isolated
human cells and recombinant enzymes establishing potential ori-
gins of novel compounds isolated from resolving exudates in vivo.
Along these lines, hypoxic human endothelial cell COX-2 con-
verted DHA to 13-hydroxy-DHA, which switched with ASA to
17R-HDHA. Human neutrophils transformed 17R-hydroxy-DHA
into two series of di- and trihydroxy products; one initiated via
oxygenation at carbon 7 and the other at carbon 4 (Serhan et al.,
2002). The conversion of 17R-HDHA by human PMNs displayed
similar features as those established for the conversion of AA to
LTB4 or LXs as well as the 18R series of EPA products. These were
termed the “aspirin-triggered” D-series Rv (Serhan et al., 2002).
Remarkably, in the absence of aspirin, D-series Rv carrying the
17S-hydroxy group were identified in murine exudates and iso-
lated human cells (Serhan et al., 2002; Hong et al., 2003). The enzy-
matic pathway leading to the formation of 17S- and 17R-RvD1 is
shown in Figure 3. Following the complete organic synthesis, the
stereochemistry of 17S-, 17R-RvD1, and RvD2 were established as
7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-DHA (17S-RvD1),
7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E,19Z-DHA (17R-RvD1;
Sun et al., 2007), and 7S, 16R, 17S-trihydroxy-4Z, 8E, 10Z, 12E,
14E, 19Z -DHA (RvD2; Spite et al., 2009a). Additional members
of this family were identified (RvD3–RvD6). Each of these arises
by similar biosynthetic routes, but has distinct chemical structures
and potentially additional bioactions that are now being unveiled
(Chiang et al., 2012). Importantly, both RvE1 and RvD1 were iden-
tified in circulating blood of healthy donors by (Psychogios et al.,
2011) as part of the Serum Metabolome Project.
THE (NEURO)PROTECTINS
In addition to D-series Rvs, DHA also serves as precursor of a new
family of LM characterized by a conjugated triene system and two
alcohol groups called PD. The name PD accounts for their pro-
tective actions observed in neural tissues and within the immune
system, while the prefix neuro PD gives the tissue localization and
site of action. The structure of the founding member of this family,
PD1, was first disclosed in a report on the isolation and elucida-
tion of Rv (Serhan et al., 2002; Hong et al., 2003), and its complete
stereochemistry later established as 10R,17S-dihydroxy-docosa-
4Z,7Z,11E,13E,15Z,19Z -hexaenoic acid (Serhan et al., 2006). In
addition to PD1, several stereo- and positional isomers that also
possess lower bioactivity than PD1 were identified in human and
mouse tissues. These include 10S,17S-diHDHA, 4S,17S-diHDHA,
7S,17S-diHDHA, and 22-hydrox-10,17S-docosatriene (a putative
inactivation product of PD1; Serhan et al., 2002; Hong et al.,
2003). The geometry of the double bonds in PD1, their posi-
tions during biosynthesis, and chirality of C10 indicate that PD1
biosynthesis proceeds through a C16(17)-epoxide intermediate
and requires specific enzymatic steps to generate the potent bioac-
tive molecule from DHA, as confirmed by the isolation of alcohol
trapping products as well as two vicinal diol 16,17-docosatrienes
as minor products of PD1 biosynthesis (Hong et al., 2003; Ser-
han et al., 2006). Recently, a novel aspirin-triggered COX-2 dri-
ven pathway was reported that biosynthesizes the 17R-epimeric
form of PD1 from DHA (Marcheselli et al., 2003; Figure 3). The
total organic synthesis and complete stereochemical assignment
of AT-PD1 (10R,17R- dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z -
hexaenoic acid) were recently achieved. Both PD1 and AT-PD1
reduced leukocyte infiltration in murine peritonitis, reduced PMN
transmigration with endothelial cells, and enhanced efferocytosis
of apoptotic PMN by human MΦ (Serhan et al., 2006). These are
the hallmark actions of a SPM carrying both anti-inflammatory
and pro-resolving actions demonstrable both in vitro and in vivo.
MARESINS
MΦs have pivotal roles in orchestrating the return to home-
ostasis (Gordon, 2007) and biosynthesize SPM that enhance
their pro-resolving and homeostatic functions. For example, MΦ
ingesting apoptotic cells initiate the biosynthesis of LXA4, RvE1,
and PD1 but not LTB4 (Freire-de-Lima et al., 2006; Schwab et al.,
2007). In addition, a new family of SPM biosynthesized by MΦs
was identified (Serhan et al., 2009). Unbiased LM LC-MS/MS-
based metabololipidomics during self-limited peritonitis led to
the identification of a novel pathway that converted DHA into
14-hydroxy DHA (HDHA). Experiments with 12/15-LO−/− mice
or with LO inhibitor confirmed that 14-HDHA production was
via a DHA carbon 14 lipoxygenation pathway. Freshly prepared
14-H(p)DHA is rapidly converted by isolated human and mouse
MΦ into a new set of bioactive products, whose molecular struc-
ture was established (Serhan et al., 2009) and recently confirmed by
matching of biogenic material with those prepared by total organic
synthesis (Serhan et al., 2012). The major product of this new path-
way proved to be 7,14-dihydroxydocosa-4Z,8E,10E,12Z,16Z,19Z -
hexaenoic acid, denoted MaR (macrophage mediator in resolving
inflammation) 1 (first in the family; MaR1; Serhan et al., 2009).
Similar to that of other potent SPM, MaR1 biosynthesis proceeds
via an epoxide intermediate, specifically the MaR1 13,14-epoxide
intermediate, that was demonstrated by trapping experiment and
with 18O-containing molecular oxygen O2 that opens during enzy-
matic conversion to MaR1 keeping the double bond geometry and
chirality of carbon 7 and 14.
In addition to MaR1 in resolving murine exudates, a novel
double dioxygenation product was isolated and identified,
7S,14S-dihydroxydocosa-4Z,8E,10Z,12E,16Z,19Z-hexaenoic acid
(denoted 7S,14S-diHDHA), formed by consecutive lipoxygena-
tion of 14-HDHA, was also identified using molecular oxygen
incorporation, and proved bioactive but less potent in activity than
MaR1 in stimulating efferocytosis with human cells (Serhan et al.,
2009, 2012). MaR1 and RvE1 are also potent stimulators of organ
regeneration using a planaria regeneration system (Serhan et al.,
2012). Hence, SPM are primordial molecules that signal from the
inflammatory site to generate the aftermath of inflammation and
tissue injury.
GPCRs FOR SPM IN ANTI-INFLAMMATION AND RESOLUTION
GPCRs FOR LXs
The first evidence for receptor-mediated actions of LXA4 arises
from studies with Santosh Nigam when he was on sabbatical in the
Serhan Lab at BWH in the late 1980s, which demonstrated stimula-
tion of rapid lipid remodeling and pertussis toxin (PTX)-sensitive
release of arachidonate in PMN treated with LXA4 (Nigam et al.,
1990). To examine the molecular basis of these actions, synthetic
[11,12-3H]-LXA4 was prepared and used to demonstrate specific
and reversible binding to intact human PMN with a K d∼ 0.5 nM.
[3H]-LXA4 binding was stereoselective as LXB4, LTB4, 6S-LXA4, or
11-trans-LXA4 did not compete for LXA4 binding, while cysteinyl
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LT C4 and D4 partially displaced bound labeled LXA4 (Fiore et al.,
1992). Screening of cDNA clones from differentiated HL60 human
cells lines led to the identification of formyl peptide receptor like-
1, a homolog of formyl receptor, as putative LXA4 GPCR (Fiore
et al., 1994). This receptor has recently been coined ALX/FPR2
by the international nomenclature committee in light of its high
affinity for LXA4 (Ye et al., 2009).
Human FPR2/ALX is highly expressed in myeloid cells and at
a lower extent in lymphocytes, dendritic cells, and resident cells
(Chiang et al., 2006). Orthologs of the human FPR2/ALX have
been identified in mice (Takano et al., 1997) and rats (Chiang
et al., 2003). In addition to LXA4, FPR2/ALX is activated by the
glucocorticoid-induced protein annexin-1 and its N-terminal pep-
tides (Perretti et al., 2002), representing the prototype of GPCR
able to coordinate anti-inflammatory and pro-resolving activi-
ties of both lipid and peptide ligands. Genetic manipulation of
ALX/FPR2 and its ortholog in mice has provided evidence for
the essential role of this GPCR in controlling immune responses.
Indeed, myeloid-driven overexpression of human FPR2/ALX in
transgenic mice resulted in a reduced neutrophil infiltration dur-
ing zymosan-induced peritonitis (Devchand et al., 2003), whereas
ALX/FPR2−/−mice have an exacerbated inflammatory phenotype
and delayed resolution (Dufton et al., 2010).
More strikingly, ATL and FPR2/ALX expression levels dic-
tate both the magnitude and duration of acute inflammation in
humans (Morris et al., 2010). Hence, mechanisms that regulate this
expression are of wide interest. Recent results from Simiele et al.
(2012) uncovered the molecular basis of ALX/FPR2 transcription
machinery, with the identification of the core promoter sequence,
the elucidation of transcription factors and epigenetic mecha-
nisms that regulate promoter activity, and the identification of the
first inheritable SNP that impairs promoter activity in individuals
at high cardiovascular risk. Notably, LXA4 upregulates ALX/FPR2
levels by activating its promoter, suggesting an additional mecha-
nism by which LXA4 exerts its bioactivities (Simiele et al., 2012).
This is particularly relevant in considering LX roles in stimulating
resolution. In addition, earlier studies demonstrated that radiola-
beled 15-epi-LXA4 binds at cysteinyl LT receptor 1 (CysLT1) with
equal affinity to LTD4, providing additional molecular mecha-
nisms for ATL dampening CysLT signals in the vasculature as well
as regulating leukocyte trafficking via ALX/FPR2 (Gronert et al.,
2001).
GPCRs FOR E-SERIES RESOLVINS
At least two GPCRs are involved in mediating RvE1 actions,namely
ChemR23 and BLT1 (Arita et al., 2005a, 2007). RvE1 binding to
ChemR23 was assessed with [3H]-labeled RvE1, which was pre-
pared by catalytic hydrogenation from synthetic diacetylenic RvE1.
[3H]-RvE1 bound to ChemR23 transfectants with high affinity
(K d= 11.3± 5.4 nM) and stereoselectivity, since RvE1 biogenic
precursors EPA and 18R-HEPE did not compete with [3H]-RvE1.
Also, the synthetic peptide fragment (YHSFFFPGQFAFS) derived
from human chemerin that was earlier reported to be a ligand for
this same receptor (Wittamer et al., 2003) displaced [3H]-RvE1
binding by∼70% when tested at 10µM concentration, suggesting
that RvE1 and chemerin share recognition sites on ChemR23
(Arita et al., 2005a; Ohira et al., 2009). [3H]-RvE1 specific binding
was also demonstrated with membrane fractions isolated from
human PMN. Radiolabeled RvE1 bound human PMN with K d
of∼50 nM and was displaced by homoligand RvE1 (K i∼ 34 nM),
LTB4 (K i= 0.08 nM), and LTB4 receptor 1 (BLT1) selective antag-
onist U-75302 (K i= 1.5 nM), but not by the chemerin peptide
(Arita et al., 2007). These results strikingly demonstrated that
RvE1 binding sites are pharmacologically distinct from ChemR23
on human PMN and prompted us to investigate whether RvE1
binds to LTB4 receptors.
In these studies, Arita et al. found that [3H]-RvE1 also gave
high affinity binding to recombinant BLT1 (K d∼ 45 nM) that
was competed by unlabeled LTB4 (K i= 3 nM). In contrast, BLT2-
overexpressing cells did not show [3H]-RvE1 binding at concen-
trations up to 10 nM. These results clearly demonstrated that RvE1
binds to BLT1 on human PMN and acts as a partial agonist to atten-
uate LTB4 incoming signals in both mouse and human leukocytes
(Arita et al., 2007).
Profiling for tissue distribution of human ChemR23 showed
expression of this GPCR in brain, kidney, cardiovascular, gastroin-
testinal, and myeloid tissues (Arita et al., 2005a). More recently,
direct evidence for ligand-receptor interactions of RvE1 and its
epimer 18S-RvE1 was provided using ChemR23 and BLT1 β-
arrestin cells. In this system,cells were engineered to co-express aβ-
arrestin protein tagged with an inactive moiety of β-galactosidase
enzyme together with a candidate GPCR fused to the short Pro-
Link peptide derived from β-galactosidase. In the presence of lig-
and, in this context RvE1 activates GPCR interacts with β-arrestin,
bringing to proximity two inactive portions of β-galactosidase
and reconstituting the fully active enzyme. The activity of this
enzyme, which is stoichiometrically dependent on GPCR-ligand
interaction, is monitored with a chemiluminescence detection sys-
tem. With ChemR23 β-arrestin cells, 18S-RvE1 dose-dependently
activated ChemR23 receptor, with EC50 (∼6.3 pM) lower than
that obtained with RvE1 (∼0.14 nM). 18S-RvE1 also antago-
nized LTB4-mediated BLT1 activation with higher potency and
efficacy than RvE1 in BLT1 β-arrestin cells (Oh et al., 2011).
Hence, RvE1 and 18S-RvE1 can share the same site(s) of spe-
cific binding to human ChemR23 as well as BLT1 and thus suggest
location-dependent mechanisms in their signaling capabilities.
RvE2 exerts potent and cell-specific bioactions on human
leukocytes (Tjonahen et al., 2006; Oh et al., 2012). Recently,
tritium-labeled [3H]-RvE2 was synthesized and gave comparable
K d (∼25 nM) with other SPM in isolated human PMN. In addi-
tion, using ChemR23 and BLT1 β-arrestin cells, RvE2 was found
to share, at least in part, receptors with RvE1 (Oh et al., 2012).
GPCRs FOR D-SERIES RESOLVINS
RvD1 activates its own GPCR and does not activate ChemR23.
RvD1 exerts specific bioactivities on human PMN, namely reduc-
tion of F-actin polymerization, that are inhibited by PTX but
not cholera toxin, whereas it did not stimulate Ca2+ release nor
activate cAMP in human PMN (Krishnamoorthy et al., 2010).
For the purpose of investigating direct binding of RvD1 to
human PMN, [3H]-RvD1 was prepared by catalytic hydrogena-
tion of synthetic [13, 14]-acetylenic RvD1 methyl ester by custom
tritiation (American Radiolabel; Krishnamoorthy et al., 2010).
This procedure was followed by de-esterification and isolation of
the RvD1 label using RP-HPLC. [3H]-RvD1 specifically bound to
human PMN with high affinity (K d∼ 0.17 nM) and was competed
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by homoligand cold RvD1 (100%) and LXA4 (∼60%) but not
the ALX-ligand annexin-1-derived Ac2-12 peptide. In parallel,
[3H]-RvD1 also showed specific binding with human monocytes
(Krishnamoorthy et al., 2010). Since RvD1 counteracts TNF-α
in vivo, luciferase-based reporter system (Arita et al., 2005a) was
employed in functional screenings to assess the ability of selected
GPCRs (Figure 4) to transduce RvD1 signals that block NF-κB
activity in response to TNF-α.
Phylogenetically related GPCR linked to inflammation and
chemoattraction were overexpressed into HeLa cells together
with a reporter vector consisting of NF-κB promoter sequence
linked to the luciferase gene. RvD1 significantly reduced TNF-
α-stimulated NF-κB response in cells overexpressing either the
LX receptor ALX/FPR2 or the orphan, GPR32, but not other
GPCRs (e.g., BLT1, BLT2, CB1, GPR-1, FPR, and ChemR23; Krish-
namoorthy et al., 2010). Moreover, RvD1 dose-dependently acti-
vated ALX/FPR2 and GPR32 in recombinant β-arrestin cells with
EC50 in the low picomolar range (EC50∼ 1.2 pM for ALX/FPR2;
8.8 pM for GPR32; Figure 5). In contrast, RvD1 did not acti-
vate RvE1 receptor ChemR23, demonstrating the high selectivity
of these ligands for their specific GPCR (Krishnamoorthy et al.,
2010). In comparison, at equimolar concentrations, RvD1, its
epimer AT-RvD1, RvD1-carboxy-methyl ester, and a metaboli-
cally more stable analog 17 (R/S)-methyl RvD1-ME activated both
ALX/FPR2 and GPR32 with similar potencies and EC50, whereas
the biosynthetic precursor native DHA was not active with GPR32
and ALX/FPR2 in this concentration (Krishnamoorthy et al.,
2012). Of interest, the known anti-inflammatory ALX/FPR2 ago-
nist compound 43 identified by traditional medicinal chemistry
screening also activated GPR32 (EC50∼ 2.2 pM) and ALX/FPR2
(EC50∼ 2.0 pM) inβ-arrestin cells but not the ADP receptor P2Y12
(Krishnamoorthy et al., 2010). Hence, RvD1, AT-RvD1, and the
derivatives carboxy methyl ester and 17(R/S)-RvD1 directly acti-
vate ALX/FPR2 and GPR32, hereafter referred to as RvD1 recep-
tor (DRV1) following the IUPAC recommendations for recep-
tor nomenclature (Brink et al., 2003; Figure 5). Overexpression
of either ALX/FPR2 or GPR32 in human MΦs gave further
enhancement of efferocytosis in response to RvD1, while knock-
down of ALX/FPR2 or DRV1/GPR32 determined a decrease in
RvD1-stimulated phagocytosis response (Krishnamoorthy et al.,
2010).
In keeping with this, Norling et al. (2012) demonstrated that
the ability of RvD1 to reduce human PMN-endothelial cell inter-
actions is absolutely dependent on ALX/FPR2 and DRV1/GPR32.
Interestingly, actions of low concentration (1 nM) RvD1 were
dampened by DRV1/GPR32 blocking antibody, whereas at high
concentrations (10 nM) they appeared ALX/FPR2-specific. These
two receptors also have distinct responses in an activated cell envi-
ronment in that upon activation human PMN rapidly mobilized
ALX/FPR2 stored in secretory granules, but not DRV1/GPR32,
to the cell membrane. In addition, in ALX/FPR2 knockout mice
RvD1 did not exert anti-inflammatory (e.g., stop PMN infiltra-
tion) nor pro-resolving (e.g., enhancing MΦ efferocytosis) actions
(Norling et al., 2012). Hence, specific GPCRs selectively mediate
RvD1 actions with ALX/FPR2 being rapidly upregulated in PMN
that are exposed to pro-inflammatory stimuli and DRV1/GPR32
possibly conveying more homeostatic functions. With respect to
cell and tissue distribution, ALX/FPR2 is present on leukocytes
and resident cells (including MΦ, synovial fibroblasts, mesangial
cells, endothelial, and epithelial cells; Krishnamoorthy et al., 2010).
Human DRV1/GPR32 was identified in peripheral blood leuko-
cytes and arterial and venous tissues using a cDNA array. It is
mostly abundant on PMN, monocytes, and macrophages and is
also present on vascular endothelial cells (Krishnamoorthy et al.,
2010). The murine ortholog of DRV1/GPR32 is currently not
known but is present in chimpanzees. Regulatory mechanisms
of DRV1/GPR32 are of interest while those of ALX/FPR2 have
recently been uncovered (Simiele et al., 2012). Although specific
receptors for RvD2, RvD3, and RvD4 have not yet been identi-
fied, the stereoselective actions of RvD2 were inhibited by PTX
(Spite et al., 2009a), implicating the involvement of GPCRs. More
recently, Chiang et al. (2012) reported activation of RvD1-receptor
DRV1/GPR32 by RvD5, which is related biosynthetically to RvD1,
with the recombinant human DRV1.
GPCRs FOR NEURO (N)PD1/PD1
Biosynthesis of (N)PD1 occurs in neural tissues in response to
injury, ischemia-reperfusion, and exposure to β-amyloid pep-
tides (Marcheselli et al., 2003; Mukherjee et al., 2004; Bazan,
2007). In addition (N)PD1 shows protective anti-inflammatory
and pro-resolving actions within the immune system (Serhan et al.,
2002; Hong et al., 2003). Hence, it was of interest to determine
the molecular basis of (N)PD1/PD1 actions. Specific binding of
tritium-labeled (N)PD1 obtained by catalytic tritiation of syn-
thetic 15-acetylenic NPD1 methyl ester was demonstrated with
both retinal pigment cells (RPE) and human PMN. [3H]-(N)PD1
bound RPE with K d∼ 30 pmol/mg of cell protein. However, at
high concentration of radio-ligand (>10 nM), non-specific bind-
ing was evident, in line with the highly hydrophobic nature of
this compound. In these experiments, competitive binding studies
with unlabeled ligand demonstrated 90–100% displacement for
the free acid form of cold (N)PD1. In these studies (N)PD1-ME
showed a lower affinity for binding sites and ∼74% displace-
ment, while other structurally related omega-3 fatty acid-derived
compounds (17S-hydroxy-DHA, RvE1, ∆15-trans-NPD1, and
∆15-trans-NPD1-carboxy methyl ester) gave only minimal or no
displacement. Specific binding experiments with [3H]-NPD1 and
isolated human PMN proved high affinity specific binding and
showed a two-site fit for sites of high and low affinity binding
(K d≈ 25 and 200 nM). Two other SPM that bind specific receptors
on human PMN, namely LX A4 (LXA4) and RvE1, did not compete
with [3H]-NPD1 binding on these cells (Marcheselli et al., 2010).
HOW DO THE PRO-RESOLVING MEDIATORS WORK?
By definition, SPM: (a) are generated within the resolution
phase; (b) limit leukocyte infiltration; (c) enhance phago-
cytic activity of pro-resolving MΦ to remove apoptotic cells
and/or microbes; (d) stimulate the clearance of PMN from
mucosal surfaces and their anti-microbial actions. If a LM
fulfills each of these bioactivities, then it belongs to the
genus of SPM. At the cellular and molecular levels, SPM dis-
play distinct modes of action on PMN and monocyte/MΦs,
which can be demonstrated with isolated cells. Each SPM
(RvE1, RvE2, and RvD1) stimulates a rapid shape change of
human leukocytes that reflects ligand-receptor responses and
cytoskeletal events that ultimately limit the PMN to diapedesis
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FIGURE 4 | Identification of RvD1 GPCR. (A) Phylogenetic tree shows
similarities in the amino acid sequences of human GPCRs closely related to
LXA4, RvE1, and LTB4 receptors (left panel). Cluster was generated with the
ClustalW2 software (www.ebi.ac.uk/Tools/clustalw2). Protein sequences
were deduced from the NCBI database and receptor nomenclature followed
the IUPAR classification for GPCR. (B) For functional screening and
identification of RvD1 receptor, GPCRs were cloned in pcDNA3 vector and
overexpressed in human HeLa cells cotransfected with pNF-κB luciferase
plasmid. Cells were treated with RvD1 and TNF-α (see inset in the right panel).
RvD1 reduces TNF-α-stimulated NF-κB activation in DRV1/GPR32 and
ALX/FPR2 receptor-overexpressing cells, while cells transfected with other
related GPCRs (e.g., BLT1, BLT2, CB1, GPR-1, FPR, and ChemR23) did not
significantly inhibit TNF-α-induced NF-κB luciferase activity on addition of the
ligand RvD1. The results illustrated are expressed in luminescence units
subtracted from pNF-κB and pcDNA3 empty vector (*P < 0.05 vs.
BLT2-transfected cells).
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FIGURE 5 | Structure-activity relationship of RvD1, AT-RvD1, and
DHA on ALX/FPR2 and DRV1/GPR32 receptors. Activation of
ALX/FPR2 and DRV1/GPR32 was determined using the β-arrestin cell
system. This system is engineered by stably expressing the target
ALX/FPR2 or DRV1/GPR32 tagged with the β-galactosidase Pro-Link
peptide. Cells also co-expressed the β-arrestin protein linked to the
β-galactosidase EA fragment. In the presence of ligand, activated GPCR
interacts with β-arrestin, bringing to proximity the EA and Pro-Link
fragments, forming a functional enzyme. β-galactosidase activity is
measured by adding the substrate and generating a chemiluminescent
signal that is stoichiometrically associated to ligand dependent GPCR
activation (see text and Krishnamoorthy et al., 2010 for further details).
Dose-response curves show activation of ALX/FPR2 (A) and
DRV1/GPR32 (B) receptors by RvD1, AT-RvD1, but not DHA determined
using the β-arrestin cell system. Results are mean (±SEM) from n=4
to 6. RLU, relative luminescence unit.
in vivo, hence reducing inflammation and tissue damage (Dona
et al., 2008; Kasuga et al., 2008; Oh et al., 2012) and pre-
pare the macrophages to enhance phagocytosis of both apop-
totic cells and microbes (Schwab et al., 2007; Ohira et al.,
2009).
The best examples of these pro-resolving cellular mechanisms
studied to date are for the Rv ligands RvE1 and RvD1. In the case of
RvE1, its direct binding to the human recombinant GPCR denoted
ChemR23, an RvE1 receptor, activates the receptor with the sub-
sequent regulation of Akt intracellular signaling pathway and
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phosphorylation signaling of proteins that increase phagocytosis
(Ohira et al., 2009). In the case of RvD1, the ligand reduces actin
polymerization in isolated human PMN in a PTX-sensitive man-
ner (Krishnamoorthy et al., 2010), diminishes surface expression
of CD11b involved in leukocyte adhesion to endothelial cells
(Krishnamoorthy et al., 2010) as does RvE1 (Dona et al., 2008),
evokes a shape change and stops chemoattractant-initiated PMN
migration observable at a single cell level with human cells iso-
lated within microfluidic chamber systems (Kasuga et al., 2008).
Of note, LXA4 also stops PMN chemotaxis in vitro (reviewed in
Serhan, 2005), while it induces rapid activation of small GTPases
and redistribution of cytoskeletal proteins (e.g., MYH9, F-actin)
in human monocyte-derived MΦs during phagocytosis (Maderna
et al., 2002; Reville et al., 2006). Hence, there appears to be a general
mechanism on how pro-resolving molecules work to achieve their
potent anti-inflammatory and pro-resolution actions, namely
via SPM coupling to distinct high affinity receptors that evoke
cell-type and specific intracellular pathways.
Besides these general actions, each SPM possesses additional
specific activities (see Table 1; Fredman and Serhan, 2011). Given
the important protective function of acute inflammation to fight
infections or dangers from within and the need to safeguard
the host from an uncontrolled reaction, it is not surprising that
SPM have some bioactions overlapping in target tissues and spe-
cific cell types. In addition, the sites of biosynthesis for each
SPM and the degree of cell distribution of their GPCRs may
underlie selectivity and specificity of the pro-resolving system.
In experimental models of inflammation and resolution, SPM
proved to be stereoselectively active in the nano- to low micro-
gram dose range to control inflammation, limit tissue damage,
shorten resolution intervals, promote healing, and alleviate pain
(Table 1). In order to define resolution in unbiased, quantitative
terms, mathematical resolution indices were introduced for deter-
mining the cellular changes in exudates, i.e., T max, time point
of maximum PMN infiltration (Ψmax); T 50, time necessary to
achieve 50% reduction in PMN number (Ψ50) from Ψmax; res-
olution interval (Ri=T 50−T max), time interval between T max
and T 50 (Bannenberg et al., 2005). The introduction of reso-
lution indices permits the evaluation of pro-resolution bioac-
tions of endogenous chemical mediators or pharmacological
agents (Schwab et al., 2007; Haworth et al., 2008; Navarro-Xavier
et al., 2010). These results first demonstrate the possibility to
pharmacologically manipulate resolution and stimulate resolu-
tion. Along these lines, results from the first human Phase I–
II clinical trials demonstrated the safety and efficacy of a Rv
analog that reduces both signs and symptoms of dry eye syn-
drome (http://Clinicaltrials.Gov Identifier: NCT00799552) and
have moved forward to Phase III clinical trial with Celtic Ther-
apeutics. Dye eye syndrome is a chronic illness commonly treated
with the immune-suppressant cyclosporine, providing evidence
that SPM have the potential to treat a broad array of human
diseases.
Acute inflammation following tissue injury, surgery, or infec-
tions causes pain (Majno and Joris, 1996). Peripheral sensitization
of primary sensory neurons is induced by inflammatory mediators
released after tissue insults, such as bradykinin, prostaglandins,
nerve growth factors (NGF), pro-inflammatory cytokines such
as TNF-α, interleukin (IL)-1β and IL-6, and pro-inflammatory
chemokines (Stein et al., 2009). The contribution of PGE2 and I2
led to the use of NSAID (e.g., naproxen, ibuprofen) and selective
COX-2 inhibitors as analgesic. Since SPM are potent regulators of
acute inflammation and pro-inflammatory mediators (including
PGs, TNF-α, and IL-1β), and since COX-2 inhibitors are resolution
toxic (Schwab et al., 2007), it was of interest to investigate whether
SPM could control inflammation associated and chronic pain. The
initial report from Svensson et al. (2007) on the antinociceptive
actions of LXA4 was followed by further studies demonstrat-
ing that Rvs, PD, and also MaR1 have potent analgesic activities
when administered both locally and systematically (Xu et al., 2010;
Huang et al., 2011; Lima-Garcia et al., 2011; Park et al., 2011; Ser-
han et al., 2012). Notably, the exquisite potent actions of SPM,
which proved as effective as morphine and COX-2 inhibitor NS-
398 at much lower doses (Xu et al., 2010), occur without altering
basal sensitive perception, unlike other anesthetics used to con-
trol pain during surgery. Hence it appears possible to resolve pain
signaling as well as inflammation.
Complete resolution requires regeneration of destroyed tissues
without affecting their functionality as in the case of fibrosis or
scarring. Pro-resolving MΦ play key functions in tissue remodel-
ing under both homeostatic (e.g., post parturition) and patholog-
ical (e.g., removal of microbes from infected tissues) conditions
(Honn et al., 1989; Majno and Joris, 1996; Gordon, 2007). In this
regard, SPM are of considerable interest in view of their roles in
regulating MΦ activities. For instance, LX, Rv, and PD stimu-
late the non-phlogistic efferocytosis by MΦ (Godson et al., 2000;
Schwab et al., 2007; Hong et al., 2008; Krishnamoorthy et al.,
2010; Oh et al., 2011). In addition, RvD1 regulates MΦ accumu-
lation in diabetic obese mice (Hellmann et al., 2011) and reduces
arthritic pain (Xu et al., 2010; Lima-Garcia et al., 2011). Failure
in the MΦ-driven pro-resolution program can support persis-
tent inflammation associated with many human diseases, such as
periodontitis. In keeping with this, recent reports indicate that
MΦ from localized aggressive periodontitis have impaired phago-
cytosis and persistent inflammation that is rescued with RvE1
(Fredman et al., 2011). In addition to enhancing MΦ phagocy-
tosis, MaR1 biosynthesized in vivo during tissue injury repair also
accelerated tissue regeneration in planaria (D. tigrina) after sur-
gical head removal (Serhan et al., 2012). Of note, these actions of
MaR1 were inhibited by PTX, indicating the involvement of GPCR
and related signaling in this process (Serhan et al., 2012).
miRNAs IN RESOLUTION CIRCUITS
Results from the Serhan laboratory at Brigham and Women’s
Hospital-Harvard Medical School demonstrated for the first time
that SPM are operative in resolution and act locally to control
leukocyte trafficking, regulate chemical mediators (e.g., cytokines,
chemokines, and lipid autacoids), and expedite the return to
homeostasis. Since microRNA (miRNAs) have emerged as the fine
tuners of many cellular processes, including immune responses
and cancer, it was of interest to investigate whether they also
played roles in resolution and SPM-regulated specific miRNA
as part of their mechanisms of action. To identify a miRNA
signature of resolution in self-resolving exudates, a strategy with
resolving exudates from murine peritonitis was used (Figure 6).
Zymosan A particles from S. cerevisiae, a Toll-like receptor 2 and
4 ligand, were injected i.p. and peritoneal exudates collected to
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Table 1 | Bioactions of SPM.
SPM Disease model Mechanism of action Reference
Lipoxin A4/ATL Mouse/dermal inflammation Inhibits neutrophil recruitment and vascular leakage Takano et al. (1997)
Mouse/dorsal air pouch Inhibits neutrophil recruitment Clish et al. (1999)
Rabbit/periodontitis Reduces PMN infiltration and prevents connective
tissue and bone loss
Serhan et al. (2003)
Mouse/peritonitis Inhibits neutrophil recruitment and lymphatic removal of
phagocytes
Bannenberg et al. (2005) and
Schwab et al. (2007)
Mouse/colitis Attenuates pro-inflammatory gene expression and
reduces severity of colitis, inhibits weight loss,
inflammation, and immune dysfunction
Gewirtz et al. (2002)
Mouse/asthma Inhibits airway hyper-responsiveness and pulmonary
inflammation
Levy et al. (2002)
Mouse/cystic fibrosis Decreases neutrophilic inflammation, pulmonary
bacterial burden, and disease severity
Karp et al. (2004)
Mouse/ischemia/reperfusion (I/R) Attenuates hind limb I/R-induced lung injury.
Detachment of adherent leukocytes in mesenteric I/R
vessels. Reduces myocardial infarct size and area at risk
in myocardial I/R
Scalia et al. (1997) and Chiang
et al. (1999)
Mouse/cornea Accelerates cornea re-epithelialization, limits sequelae
of thermal injury (i.e., neovascularization, opacity) and
promotes host defense
Gronert et al. (2005)
Mouse/angiogenesis Reduces angiogenic phenotype: endothelial cell
proliferation and migration
Fierro et al. (2002)
Mouse/bone marrow transplant (BMT) Protects against BMT-induced graft-versus-host
diseases (GvHD)
Devchand et al. (2005)
Rat/glomerulonephritis Reduces leukocyte rolling and adherence; decreases
neutrophil recruitment
Papayianni et al. (1995)
Rat/hyperalgesia Prolongs paw withdraw latency, reducing hyperalgesic
index, and reduces paw edema
Svensson et al. (2007)
Rat/pleuritis Shortens the duration of pleural exudation Bandeira-Melo et al. (2000)
Mouse/tumor growth Suppresses the growth of transplanted tumors in mice;
inhibits angiogenesis
Chen et al. (2010)
Mouse/allograft rejections Prevents acute rejection of vascularized cardiac and
renal allografts
Levy et al. (2011)
Mouse/arthritis Inhibits edema formation and PMN influx, reduces
TNFα and LTB4 levels
Conte et al. (2010)
Rat/acute pancreatitis Reduces intercellular adhesion molecule 1 (ICAM-1)
and NF-κB p65 expression in the pancreas, and
expression of ICAM-1 in the lungs
Zhou et al. (2011)
Zebrafish/mycobacterial infection Reduces bacterial burden and growth; improves
microbial containment by phagocytes
Tobin et al. (2012)
Resolvin E1 Mouse/dorsal air pouch Inhibits neutrophil recruitment Serhan et al. (2000a)
Mouse/peritonitis Inhibits neutrophil recruitment, regulates
chemokine/cytokine production, and promotes
lymphatic removal of phagocytes
Arita et al. (2005a),
Bannenberg et al. (2005), and
Schwab et al. (2007)
Rabbit/periodontitis Reduces PMN infiltration, prevents connective tissue
and bone loss, promotes healing of diseased tissues,
and promotes regeneration of lost soft tissue and bone
Hasturk et al. (2006, 2007)
Mouse/retinopathy Protects against neovascularization Connor et al. (2007)
Mouse/colitis Decreases PMN recruitment and pro-inflammatory
gene expression; improves survival and reduces weight
loss; favors LPS-detoxification through induction of
intestinal alkaline phosphatase
Arita et al. (2005b), Campbell
et al. (2010), and Ishida et al.
(2010)
(Continued)
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Table 1 | Continued
SPM Disease model Mechanism of action Reference
Mouse/asthma Reduces IL-23 and IL-6, and increases IFNγ and LXA4
in lungs to dampen airway inflammation; decreases
eosinophil and lymphocyte recruitment
Aoki et al. (2008, 2010) and
Haworth et al. (2008)
Mouse/obesity Regulates adipokines and protects against liver
steatosis
Gonzalez-Periz et al. (2009)
Mouse/inflammatory pain Inhibits spontaneous pain, and heat and mechanical
hypersensitivity
Xu et al. (2010)
Rat/cardiac ischemia/reperfusion injury Reduces infarct size Keyes et al. (2010)
Mouse/allograft rejections Prevents acute rejection of vascularized cardiac and
renal allografts
Levy et al. (2011)
Mouse/dry eye Promotes tear production, corneal epithelial
integrity, and decreases in inflammatory inducible
COX-2. RvE1 inhibits keratocyte transformation to
myofibroblasts and lowers the number of
monocytes/macrophages
Li et al. (2010)
Mouse/herpes simplex virus Reduces severity of herpes simplex virus-induced
ocular lesions, reduces angiogenesis, and stromal
keratitis
Rajasagi et al. (2011)
Resolvin D1 Mouse/peritonitis Inhibits neutrophil recruitment; shortens resolution
interval; regulates miRNAs and target genes in
resolving exudates; reduces LTB4, PGD2, PGF2α,
and TXA2 in peritoneal exudates
Hong et al. (2003), Sun et al.
(2007), Spite et al. (2009b),
Recchiuti et al. (2011),
Krishnamoorthy et al. (2012),
and Norling et al. (2012)
Mouse/E. coli (peritoneal) and
S. aureus (skin) infection
Reduces bacterial titers and hypothermia; increased
survival; enhances microbial containment and killing
by phagocytes; lowers antibiotic requirement;
shortens resolution interval
Chiang et al. (2012)
Mouse/dorsal air pouch Inhibits neutrophil recruitment Serhan et al. (2002) and Hong
et al. (2003)
Mouse/kidney ischemia-reperfusion Protects from ischemia/reperfusion-induced kidney
damage and loss of function; regulates macrophages
Duffield et al. (2006)
Mouse/retinopathy Protects against neovascularization Connor et al. (2007)
Mouse/inflammatory pain Inhibits spontaneous pain, heat, and mechanical
hypersensitivity; selectively blocks TRPV1 and
TRPA1-mediated pain
Xu et al. (2010) and Park et al.
(2011)
Mouse/obesity Reduces inflammatory cytokines in adipose tissue
macrophages; stimulates M2 macrophage
differentiation; promotes resolution of adipose tissue
inflammation
Titos et al. (2011)
Mouse/T2 diabetes Reduces macrophage accumulation in adipose
tissue; ameliorates insulin sensitivity
Hellmann et al. (2011)
Rats/post-operative pain Reduces post-operative pain, tactile allodynia, and
hyperalgesia
Huang et al. (2011)
Mouse/pain Attenuates agonist-induced and inflammatory pain
behaviors; inhibits TRPA1, TRPV3, and TRPV4
receptors; does not affect basal sensitivity
Bang et al. (2010) and Xu et al.
(2010)
Mouse/acute lung injury Blocks leukocyte infiltration and reduces cytokine
levels in BALF
Wang et al. (2011)
Mouse/corneal inflammation Reduces leukocyte infiltration and hemangiogenesis Jin et al. (2009)
(Continued)
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Table 1 | Continued
SPM Disease model Mechanism of action Reference
AT-RvD1 Mouse/colitis Reduces disease activity index, PMN number, and
pro-inflammatory levels
Bento et al. (2011)
Attenuates pain signals and behaviors by blocking
TRPV3
Bang et al. (2012)
Rats/arthritic pain Possesses anti-hyperalgesic effects upon systemic
administration. Decreases TNF-α and IL-1β production
Lima-Garcia et al. (2011)
Resolvin D2 Mouse/peritonitis Blocks further PMN infiltration into the peritoneum Spite et al. (2009a)
Mouse/sepsis Prevents hypothermia, decreases bacterial load in the
blood and peritoneum, promotes survival
Spite et al. (2009a)
Mouse/colitis Improves disease activity index, weight loss, and
colonic PMN infiltration. Reduces pro-inflammatory
levels
Bento et al. (2011)
(Neuro)Protectin D1 Mouse/peritonitis Inhibits neutrophil recruitment and regulates
chemokine/cytokine production
Bannenberg et al. (2005) and
Serhan et al. (2006)
Promotes lymphatic removal of phagocytes; regulates
T-cell migration; enhances CCR5 expression on
apoptotic leukocytes
Ariel et al. (2005, 2006) and
Schwab et al. (2007)
Mouse/asthma Protects from lung damage, airway inflammation, and
hyper-responsiveness
Levy et al. (2007)
Human/asthma PD1 is generated in human asthmatic patients Levy et al. (2007)
Mouse/kidney ischemia/reperfusion Protects from ischemia/reperfusion-induced kidney
damage and loss of function; regulates macrophages
Duffield et al. (2006)
Mouse/retinopathy Protects against neovascularization Connor et al. (2007)
Rat/ischemic stroke Inhibits leukocyte infiltration, NF-κB, and COX-2
induction
Marcheselli et al. (2003)
Human/Alzheimer’s disease Diminished PD1 production in human Alzheimer’s
disease
Lukiw and Bazan (2008)
Mouse/liver injury Protects from necroinflammatory liver injury Gonzalez-Periz et al. (2009)
Mouse/Alzheimer’s disease Downregulates inflammatory genes; reduces
amyloidogenic Aβ42 cleavage; protects from
apoptosis
Zhao et al. (2011)
Maresin-1 Mouse/peritonitis Blocks PMN infiltration into the peritoneum Serhan et al. (2009)
Planaria/tissue regeneration Stimulates tissue regeneration post surgical damage Serhan et al. (2012)
Mouse/pain Reduces pain Serhan et al. (2012)
monitor temporal changes in both leukocyte numbers and com-
position. Rapidly after zymosan injection, leukocytes infiltrated
the peritoneal cavity during the onset phase of acute inflam-
mation (4 h), reaching a maximum (∼22.0× 106) at ∼12 h and
declined at 24–48 h. Differential analysis with flow cytometry
confirmed that the majority of leukocytes in exudates at 4 and
12 h were PMN (Ly-6Ghigh/CD11b+; ∼10.0× 106 cells at 4 h
and ∼15× 106 cells at 12 h). PMN number declined during the
resolution phase 24 and 48 h after initiation of peritonitis. Con-
versely, resident peritoneal MΦs (F4/80+cells), which represent
the main leukocyte population in naive mice peritonea (Win-
yard and Willoughby, 2003), were not detected in exudates at 4 h.
Monocytes (Ly-6Glow/CD11bhigh cells) gradually increased at 12 h
and differentiated into MΦs, consistent with their pro-resolution
functions (Gordon, 2007), reaching∼60% of exudate leukocytes at
48 h. Because it is important to define resolution in unbiased terms,
resolution indices, introduced by Bannenberg et al. (2005), were
calculated (i.e.,Ψmax∼ 15.0× 106; T max∼ 12 h; Ψ50∼ 7.5× 106;
T 50∼ 30 h; Ri∼ 18 h; Figure 7) to characterize the resolution
phase and determine temporal changes in miRNA expression dur-
ing this time interval. Hierarchical clustering grouped the ∼300
miRNAs examined into distinct clusters based on their relative
abundance at the different time intervals, indicating that specific
miRNAs are temporally regulated during acute inflammation and
its natural self-limited resolution.
In these studies, miR-21, miR-146b, miR-208a, and miR-219
were significantly regulated at 12 and 24 h compared to 4 h
(Figure 7), suggesting a role in resolution. For instance, miR-21
proved to be critical for the production of anti-inflammatory IL-10
in experimental peritonitis (Sheedy et al., 2010), corroborating
our findings. Next, resolution indices were used to pinpoint RvD1
actions in resolution. RvD1, administered in its pro-drug carboxy
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FIGURE 6 | Strategy for identification of RvD1-GPCR circuits. Self-limited
zymosan-stimulated mouse peritonitis was used to obtain resolving
exudates that were collected 4, 12, 24, and 48 h after zymosan A injection
for temporal and differential analysis of leukocyte counts and phenotype,
miRNA real-time PCR analysis, and lipidomics as in Recchiuti et al. (2011)
and Krishnamoorthy et al. (2012). Candidate miRNAs, defined as those that
were temporally and/or RvD1-regulated, were confirmed using
bioinformatics and prediction of target genes, real-time PCR, as well as
overexpression in human MΦs. The Ingenuity Pathway Analysis Software
database was used to identify circuits of molecules and biological functions
controlled by RvD1-regulated miRNAs and target genes (see text; Recchiuti
et al., 2011 for analysis details).
methyl ester form, significantly lowered the Ψmax (from 15.0 to
11.5× 106), and accelerated or shortened the Ri by ∼4 h. Quan-
titative real-time PCR analyses carried out with exudates from
zymosan- and zymosan plus RvD1-treated mice revealed that
RvD1 temporally controls the specific sets of pro-resolving miR-
NAs miR-21,miR-146b,miR-208a,and miR-219 (coined resolution
miRs) in exudates in vivo. For translation to humans, actions
of RvD1 on these miRNAs were assessed in ALX/FPR2 and
DRV1/GPR32-overexpressing isolated human cells, namely MΦ,
the master regulators of resolution. Notably, RvD1 also regulated
miR-21, -146b, -208a, and 219 in a GPCR-dependent manner. In
order to identify target molecules of RvD1-GPCR-regulated miRs,
we overexpressed miR-146b, -208a, and -219 in human MΦ for
real-time PCR analysis to assess which mRNAs were significantly
regulated.
Since miRNAs can regulate mRNAs and protein levels of
hundreds of genes involved in biological processes (Bartel,
2009), miR-target genes were clustered using the Ingenuity
Pathway Analysis knowledge database based on their physi-
cal and/or functional interactions, creating the first identified
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FIGURE 7 | Resolution indices and miRNA signature of resolution. (A)
Resolution indices were calculated as in (Bannenberg et al., 2005) using PMN
numbers in peritoneal exudates from mice treated with zymosan alone (red
line) and zymosan plus RvD1 (blue line) at indicated time intervals:T max, time
of maximum PMN infiltration (Ψmax);T 50, time to achieve 50% reduction in
PMN number (Ψ50) from Ψmax; R i, resolution interval (T 50 −T max; time interval
betweenT max andT 50). RvD1, administered at the beginning of peritonitis,
significantly lowers amplitude (i.e., Ψmax) and duration (T 50) of PMN infiltration,
shortening the R i by∼4h. (B) Heat map cluster represents relative expression
of ∼300 mouse miRNAs from resolving exudates determined with real-time
PCR after normalization with housekeeping small RNAs (snoRNA251,
snoRNA202, snoRNA142, and Rnu6). Relative expression intensities are
indicated in a green-red color code based on ∆Ct expression values (n=3
mice/group). Temporal and RvD1-regulated miRNAs are highlighted.
RvD1-GPCR-regulated gene networks involved in inflammation
and resolution. For instance, miR-146 networks 1 and 3 included
genes of the NF-κB activation pathway (e.g., IκB kinase and
tumor necrosis factor receptor-associated factor 6) and innate
response to pathogens (e.g., Toll-like receptors, S100 protein, C-
reactive protein, peptidoglycan recognition protein; Figure 8A).
Several cytokines and chemokines (IL-8, 10, 12, interferon-α and
β) belonged to the miR-146b network 2 (Figure 8A). NF-κB is
a critical transcription factor involved in regulation of cell func-
tions in inflammation and resolution (Lawrence et al., 2001). Of
interest, RvD1 in human monocytes reduces the nuclear transloca-
tion of NF-κB, TNF-α induced phosphorylation of IκB (Recchiuti
et al., 2011), counteracts NF-κB activation in ALX/FPR2 and
DRV1/GPR32 recombinant cells (Krishnamoorthy et al., 2010),
dampens acute inflammation in murine dorsal air pouches evoked
by local administration of TNF-α (Serhan et al., 2002), and down-
regulates IKK levels in murine peritonitis (Recchiuti et al., 2011).
Therefore, regulation of miRNAs and the TNF-α-NF-κB axis
seems to be a key component in the RvD1-GPCR downstream
signaling network.
The miRNA miR-208a downregulates CD14, CD40 ligand,
PGI2 receptor, thromboxane A2 receptor, and programmed cell
death (Recchiuti et al., 2011; Figure 8B), a tumor suppressor
molecule that acts as a translational repressor of IL-10 (Sheedy
et al., 2010), consistent with the existence of a seed region for miR-
208a in the 3′ UTR of PDCD4. Notably, in self-limited peritonitis,
RvD1 reduced PDCD4 and increased IL-10 production, providing
in vivo correlates of RvD1-miR-dependent gene regulations.
The miR-219 network includes CD14 and 5-LO (Figure 8C), a
key enzyme for the biosynthesis of LTs, and SPMs. In addition, a
significant reduction in 5-LO protein levels and LTB4 production
was found in human MΦoverexpressing the RvD1-regulated miR-
219, translating findings in mouse peritonitis to the human MΦ
cell system (Recchiuti et al., 2011). Endogenous regulatory mech-
anisms of 5-LO are of wide interest given the important roles of
LTs, LXs, and Rvs in inflammation and resolution (Samuelsson,
1983; Serhan et al., 2002). In addition to transcriptional regu-
lation by cytokines and growth factors (Radmark et al., 2007),
miR-219 can provide a rapid mean to balance the abundance of
5-LO protein in cells under dynamic conditions such as during
inflammation.
RvD1 actions were also tested in genetically engineered mice in
order to obtain further evidence of ALX/FPR2-dependent action.
Transgenic mouse colonies in which human ALX/FPR2 gene was
placed under control of a CD11b promoter that drives trans-
gene expression in mature murine myeloid cells were created
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FIGURE 8 |Translation of RvD1-dependent miRNA circuits in human cells. RvD1-GPCR gene networks connecting target genes of miR-146b (A), miR-208a
(B), and miR-219 (C). Genes that are significantly down regulated in each network are indicated in red.
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FIGURE 9 | Evidence for ALX/FPR2-RvD1-dependent miRNA
pathways in vivo. Reduction in (A) PMN infiltration by RvD1 is
significantly higher in myeloid-driven human ALX-transgenic (Tg) mice
challenged with zymosan (1 mg/mouse, i.p., 24 h) than non-Tg
littermates. Results are mean±SEM from three mice/group (*P <0.05
vs. non-Tg). (B) Relative expression of miR-208a determined in resolving
exudates 24 h after zymosan alone or zymosan plus RvD1 administration
in hALX-Tg or non-Tg littermates (mean±SEM, n=3 mice/group;
**P <0.05 vs. non-Tg zymosan group; #, P < 0.05 vs. hALX-Tg zymosan
group). (C) miR-208a expression in peritoneal exudates (24 h) from
ALX/FPR2 knockout mice treated with zymosan alone or zymosan plus
RvD1.
(Devchand et al., 2003). Interestingly, total peritoneal leukocytes
at 24 h peritonitis were significantly lower in ALX/FPR2 transgenic
mice treated with zymosan alone compared to non-transgenic lit-
termates, and RvD1 administration resulted in a further significant
decrease (∼53% reduction) in peritoneal exudate leukocyte num-
bers in ALX/FPR2 transgenic mice compared to non-transgenic
littermates (Figure 9). Quantitative PCR analysis of miRNAs
isolated from peritoneal lavages collected 24 h post injection of
zymosan showed that RvD1 significantly upregulated identified
resolution miRs miR-208a and miR-219 in vivo (Recchiuti et al.,
2011), whereas it does not appear to regulate miR-21, miR-146b,
and miR-302d (Figure 9). To further investigate ALX/FPR2-
dependent actions of RvD1 in vivo, it was next tested whether
RvD1 can regulate some of these miRNAs in ALX/FPR2 knockout
mice, where LXA4 did not regulate leukocyte trafficking (Dufton
et al., 2010). In ALX/FPR2−/− mice, RvD1 did not regulate PMN
infiltration, consistent with recent results (Norling et al., 2012),
nor did it significantly alter miR-208a or miR-219 expression at
24 h (Figure 9).
Taken together, these results indicate that RvD1 controls leuko-
cyte infiltration and specific resolution phase miRs in acute
inflammation in an ALX/FPR2-dependent manner in mice and
DRV1/GPR32-dependent in isolated human cells.
SUMMATION AND CONCLUSION
It is now eminently clear that the acute inflammatory response
of the host is a highly coordinated defensive response and its
complete resolution is the ideal outcome. This ideal outcome is
achieved in self-limited inflammation by activation of endoge-
nous resolution programs that are governed in part by reso-
lution phase local chemical mediators. Excessive inflammation
can lead to chronic disorders and host damage. LM from AA,
such as PGs and LTs, can amplify the inflammatory response,
and PGE2 and D2 initiate the “class switch” that leads to the
biosynthesis of LXA4, the first member of the new genus of SPM.
SPM include several families of LM such as E-and D-series Rv
(neuro)PD, and the youngest family, the MaR, which are biosyn-
thesized from essentialω-3 fatty acids. Of interest in experimental
animal models of disease, each of the SPM can accelerate the
resolution process when administered in vivo, and their bioac-
tions are highly stereospecific, GPCR-mediated, and exerted at
low doses. SPM also reduce pain and promote tissue regenera-
tion, the ultimate goal of complete return to homeostasis. Results
from the first human clinical Phase I and II trial with a Rv
analog appear encouraging and can open new opportunities for
resolution pharmacology based on endogenous mediators to ter-
minate inflammation and treat inflammation-related diseases. We
trust that more human trials will be launched to test the notion
that stimulating resolution mechanisms can improve disease and
health status.
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